Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing

The effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect genetic rearrangements in some genes (ie, ALK, ROS1, RET and NTRK) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Conde, Esther, Rojo, Federico, Gómez, Javier, Enguita, Ana Belén, Abdulkader, Ihab, González, Ana, Lozano, Dolores, Mancheño, Nuria, Salas, Clara, Salido, Marta, Salido-Ruiz, Eduardo, de Álava, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862096/
https://www.ncbi.nlm.nih.gov/pubmed/33875457
http://dx.doi.org/10.1136/jclinpath-2021-207490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862096/
https://www.ncbi.nlm.nih.gov/pubmed/33875457
http://dx.doi.org/10.1136/jclinpath-2021-207490

Ejemplares similares